

**RECEIVED  
CENTRAL FAX CENTER**

**JAN 06 2006**

Attorney Docket No.: 10274.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schnorr et al.

Confirmation No: 8351

Serial No.: 10/676,902

Group Art Unit: 1652

Filed: October 1, 2003

Examiner: K. Gebreyesus

For: Family GH 61 Polypeptides

**CERTIFICATE OF FACSIMILE TRANSMISSION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner K. Gebreyesus, fax number (571)273-8300.

Respectfully submitted,

Date: January 6, 2006

  
Julie Tabarovsky  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

JAN 06 2006

Attorney Docket No.: 10274.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al.

Confirmation No: 8351

Serial No.: 10/676,902

Group Art Unit: 1652

Filed: October 1, 2003

Examiner: K. Gebreyesus

For: Family GH 61 Polypeptides

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed July 6, 2005.

It is respectfully requested that the time for response to the Office Action be extended for a period of three months from October 6, 2005 to January 6, 2006. The required fee for the extension is estimated to be \$1,020.

The fee for claims has been calculated as shown below:

Total:  $28 - 20 = 8 \times 50 = \$400$

Independent:  $2 - 4 = 0 \times 200 = \$0$

Total additional fee for claims required is \$400.

Please charge the required extension and claims fees, estimated to be \$1,420, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 6, 2006



Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

**RECEIVED  
CENTRAL FAX CENTER**

**JAN 06 2006**

Attorney Docket No.: 10274.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schnorr et al.

Confirmation No: 8351

Serial No.: 10/676,902

Group Art Unit: 1652

Filed: October 1, 2003

Examiner: K. Gebreyesus

For: Family GH 61 Polypeptides

**AMENDMENT UNDER 37 C.F.R. 1.111**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed July 6, 2005, please amend the above-identified application as follows:

**Amendments to the specification** begin on page 2 of this document.

**Amendments to the claims** are reflected in the listing of claims, which begins on page 3 of this document.

**Remarks and arguments** begin on page 7 of this document.

01/09/2006 STEUKEL1 00000022 501701 10676902

01 FC:1202 400.00 DA  
02 FC:1253 1020.00 DA